Asia
Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies that will be aimed at metabolic disorders.
1E Therapeutics announced $120 million seed funding, a remarkable feat for an early-stage biotech company. The funding is the largest of its kind for an Israeli biotech company.
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, and also working on monoclonal antibodies treatment.
On Wednesday, clinical-stage biotech Avistone Pharmaceuticals announced that it has raised more than $200 million of financial backing to support its business combination with Pearl Biotechnology.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
A major factor behind the success of the smallpox eradication campaign was political commitment and leadership.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Ablaze has aligned itself with RayzeBio, giving Ablaze a solid start with an in-licensing agreement to bring Rayze’s products to the greater China market.
PRESS RELEASES